First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
Clin Transl Sci. 2024 Mar;17(3):e13742. doi: 10.1111/cts.13742.ABSTRACTRelapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)33 × CD3 bispecific antibody, JNJ-67571244, was assessed to identify the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety and tolerability, and preliminary clinical activity in patients with r/rAML or r/rMDS. This first-in-human, open-label, phase I, dose-escalation/dose-expansion study included patients with r/rAML or r/rMDS who were ineligible for or had exhausted standard ther...
Source: The Medical Clinics of North America - March 18, 2024 Category: General Medicine Authors: Rupa Narayan Ana Alfonso Pi érola William B Donnellan Antonieta Molero Yordi Maher Abdul-Hay Uwe Platzbecker Marion Subklewe Tapan Mahendra Kadia Juan Manuel Alonso-Dom ínguez James McCloskey Kathryn Bradford Martin Curtis Nikki Daskalakis Christina Gut Source Type: research
SOHO State of the Art Updates and Next Questions | An Update on Higher Risk Myelodysplastic Syndromes
High-risk myelodysplastic neoplasms (abbreviated HR-MDS) are a heterogenous group of clonal myeloid-lineage malignancies often characterized by high-risk genetic lesions, increased blood transfusion needs, constitutional symptoms, elevated risk of progression to acute myeloid leukemia (AML) and therapeutic need for bone marrow transplantation. Use of blast percentage and other morphologic features to define MDS subtypes is rapidly shifting to incorporate genetics, resulting in a subset of former HR-MDS patients now being considered as AML in presence of leukemia-defining genetic alterations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Michael J. Hochman, Amy E. DeZern Source Type: research
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Blood Cancer Journal, Published online: 18 March 2024; doi:10.1038/s41408-024-01027-5Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution? (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 18, 2024 Category: Hematology Authors: Mostafa Abdallah Kaaren Reichard Naseema Gangat Ayalew Tefferi Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Higher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Michael J. Hochman, Amy E. DeZern Tags: Review Article Source Type: research
Periorbital necrotizing sweet syndrome: A report of two cases mimicking necrotizing soft tissue infections
CONCLUSION: nSS is rare and a high level of clinical suspicion as well as an understanding of its distinguishing features is necessary to avoid undue morbidity. Identification of pathergy, histopathology, microbiology, and clinical context are critical to avoid misdiagnosis of infection.PMID:38487334 | PMC:PMC10937104 | DOI:10.1016/j.ajoc.2024.102033 (Source: Herpes)
Source: Herpes - March 15, 2024 Category: Infectious Diseases Authors: Hursuong Vongsachang Carolina A Chiou Amee D Azad Lisa Y Lin Michael K Yoon Daniel R Lefebvre Anna M Stagner Source Type: research
A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant
Int J Hematol. 2024 Mar 15. doi: 10.1007/s12185-024-03751-x. Online ahead of print.ABSTRACTBloom syndrome (BS) is an autosomal recessive genetic disorder caused by variants in the BLM gene. BS is characterized by distinct facial features, elongated limbs, and various dermatological complications including photosensitivity, poikiloderma, and telangiectatic erythema. The BLM gene encodes a RecQ helicase critical for genome maintenance, stability, and repair, and a deficiency in functional BLM protein leads to genomic instability and high predisposition to various types of cancers, particularly hematological and gastrointesti...
Source: International Journal of Hematology - March 15, 2024 Category: Hematology Authors: Takuma Ohashi Hiroyoshi Kunimoto Jun Nukui Haruka Teshigawara Satoshi Koyama Takuya Miyazaki Maki Hagihara Kenji Matsumoto Eriko Koshimizu Naomi Tsuchida Haruka Hamanoue Satoko Miyatake Akihiro Yachie Naomichi Matsumoto Hideaki Nakajima Source Type: research
A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant
Int J Hematol. 2024 Mar 15. doi: 10.1007/s12185-024-03751-x. Online ahead of print.ABSTRACTBloom syndrome (BS) is an autosomal recessive genetic disorder caused by variants in the BLM gene. BS is characterized by distinct facial features, elongated limbs, and various dermatological complications including photosensitivity, poikiloderma, and telangiectatic erythema. The BLM gene encodes a RecQ helicase critical for genome maintenance, stability, and repair, and a deficiency in functional BLM protein leads to genomic instability and high predisposition to various types of cancers, particularly hematological and gastrointesti...
Source: International Journal of Hematology - March 15, 2024 Category: Hematology Authors: Takuma Ohashi Hiroyoshi Kunimoto Jun Nukui Haruka Teshigawara Satoshi Koyama Takuya Miyazaki Maki Hagihara Kenji Matsumoto Eriko Koshimizu Naomi Tsuchida Haruka Hamanoue Satoko Miyatake Akihiro Yachie Naomichi Matsumoto Hideaki Nakajima Source Type: research
Periorbital necrotizing sweet syndrome: A report of two cases mimicking necrotizing soft tissue infections
CONCLUSION: nSS is rare and a high level of clinical suspicion as well as an understanding of its distinguishing features is necessary to avoid undue morbidity. Identification of pathergy, histopathology, microbiology, and clinical context are critical to avoid misdiagnosis of infection.PMID:38487334 | PMC:PMC10937104 | DOI:10.1016/j.ajoc.2024.102033 (Source: Herpes)
Source: Herpes - March 15, 2024 Category: Infectious Diseases Authors: Hursuong Vongsachang Carolina A Chiou Amee D Azad Lisa Y Lin Michael K Yoon Daniel R Lefebvre Anna M Stagner Source Type: research
Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights
ConclusionThis study highlights the genetic dynamics in the progression from AA to hematologic malignancy. Monosomy 7’s prevalence and the occurrence of PTPN11 mutations suggest predictive and prognostic significance. Clonal evolution underscores the complexity of disease progression. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation
ConclusionThese data demonstrate that the risk factors for GvHD after DLI depend on the setting of the DLI. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 13, 2024 Category: Allergy & Immunology Source Type: research
Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
The prognostic significance of myelofibrosis (MF) grade in patients with myelodysplastic syndrome (MDS) following an allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains elusive. (Source: Journal of Translational Medicine)
Source: Journal of Translational Medicine - March 13, 2024 Category: Research Authors: Panpan Zhu, Xiaoyu Lai, Lizhen Liu, Jimin Shi, Jian Yu, Yanmin Zhao, Luxin Yang, Tingting Yang, Weiyan Zheng, Jie Sun, Wenjun Wu, Yi Zhao, Zhen Cai, He Huang and Yi Luo Tags: Research Source Type: research
Rare NUP98::PRRX1 fusion transcript in a therapy-related acute myeloid leukemia associated with del(7q) following chemotherapy for diffuse large B-cell lymphoma
Therapy-related acute myeloid leukemia (t-AML) is a serious adverse consequence in cancer treatment, including chemotherapy, radiation therapy, or immunosuppressive agents, accounting for 7% of adult AML [1,2]. The two most common leukemia-causing cytotoxic drugs include alkylating agents and topoisomerase-II inhibitors. The majority of alkylating agents-related leukemias have a longer latency of 5 –10 years and typically have a total or partial deletion of chromosome 5 [-5/del(5q)] and chromosome 7 [-7/del(7q)] and/or complex karyotype and are often present with prior myelodysplastic syndrome (MDS) and poor prognosis. (...
Source: Cancer Genetics and Cytogenetics - March 12, 2024 Category: Genetics & Stem Cells Authors: Yanfang Wang, Zhenhao Zhang, Lingli Wang, Hua Wang, Fei Dong Source Type: research
Prognostic impact of < em > SF3B1 < /em > mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284719. Online ahead of print.ABSTRACTThe revised 4th edition of the World Health Organization (WHO4R) classification lists myelodysplastic syndromes with ring sideroblasts (MDS-RS) as a separate entity with single lineage (MDS-RS-SLD) or multilineage (MDS-RS-MLD) dysplasia. The more recent International Consensus Classification (ICC) distinguishes between MDS with SF3B1 mutation (MDS-SF3B1) and MDS-RS without SF3B1 mutation; the latter is instead included under the category of MDS not otherwise specified. The current study includes 170 Mayo Clinic patients with WHO4R-d...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Faiqa Farrukh Maymona Abdelmagid Abhishek Mangaonkar Mrinal Patnaik Aref Al-Kali Michelle A Elliott Kebede H Begna Christopher C Hook William J Hogan Animesh Pardanani Mark R Litzow Rhett P Ketterling Naseema Gangat Daniel A Arber Attilio Orazi Rong He Ka Source Type: research
Prognostic impact of < em > SF3B1 < /em > mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284719. Online ahead of print.ABSTRACTThe revised 4th edition of the World Health Organization (WHO4R) classification lists myelodysplastic syndromes with ring sideroblasts (MDS-RS) as a separate entity with single lineage (MDS-RS-SLD) or multilineage (MDS-RS-MLD) dysplasia. The more recent International Consensus Classification (ICC) distinguishes between MDS with SF3B1 mutation (MDS-SF3B1) and MDS-RS without SF3B1 mutation; the latter is instead included under the category of MDS not otherwise specified. The current study includes 170 Mayo Clinic patients with WHO4R-d...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Faiqa Farrukh Maymona Abdelmagid Abhishek Mangaonkar Mrinal Patnaik Aref Al-Kali Michelle A Elliott Kebede H Begna Christopher C Hook William J Hogan Animesh Pardanani Mark R Litzow Rhett P Ketterling Naseema Gangat Daniel A Arber Attilio Orazi Rong He Ka Source Type: research
Prognostic impact of < em > SF3B1 < /em > mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284719. Online ahead of print.ABSTRACTThe revised 4th edition of the World Health Organization (WHO4R) classification lists myelodysplastic syndromes with ring sideroblasts (MDS-RS) as a separate entity with single lineage (MDS-RS-SLD) or multilineage (MDS-RS-MLD) dysplasia. The more recent International Consensus Classification (ICC) distinguishes between MDS with SF3B1 mutation (MDS-SF3B1) and MDS-RS without SF3B1 mutation; the latter is instead included under the category of MDS not otherwise specified. The current study includes 170 Mayo Clinic patients with WHO4R-d...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Faiqa Farrukh Maymona Abdelmagid Abhishek Mangaonkar Mrinal Patnaik Aref Al-Kali Michelle A Elliott Kebede H Begna Christopher C Hook William J Hogan Animesh Pardanani Mark R Litzow Rhett P Ketterling Naseema Gangat Daniel A Arber Attilio Orazi Rong He Ka Source Type: research
